Short Commentry
Wells AF, Haddad R
Abstract
The care of patients with rheumatic diseases including rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis has been revolutionized with the introduction of biologic medications including tumor necrosis factor-α inhibitors (TNFi); interleukin-6 (IL-6) antagonists; interleukin-17 (IL-17) antagonists; B cell antagonists; T cell antagonists; and Janus kinase inhibitors (JAKI)